We are live on ! Find out more
DOVA

Dova Pharmaceuticals, Inc. Common Stock
DOVA

Delisted

DOVA was delisted on the 11th of November, 2019.

Back to rankings

48 hedge funds and large institutions have $209M invested in Dova Pharmaceuticals, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 6

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

30% more capital invested

Capital invested by funds: $160M → $209M (+$48.4M)

23% more funds holding

Funds holding: 39 → 48 (+9)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
48
Holders Change
+9
Holders Change %
+23.08%
% of All Funds
1.09%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
17
Increased
17
Reduced
6
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$9.55M
2
Morgan Stanley
Morgan Stanley
New York
+$5.58M
3
PA
Perceptive Advisors
New York
+$1.51M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.24M
5
PC
Pier Capital
Connecticut
+$1.19M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.26M
2
SFM
Sphera Funds Management
Israel
-$1.9M
3
Norges Bank
Norges Bank
Norway
-$425K
4
Barclays
Barclays
United Kingdom
-$336K
5
Millennium Management
Millennium Management
New York
-$247K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$54.3M -$3.26M -119,110 -6%
PA
2
Perceptive Advisors
New York
$52.1M +$1.51M +55,000 +3%
FI
3
Fosun International
China
$20.4M – – –
BlackRock
4
BlackRock
New York
$16.6M +$9.55M +348,290 +152%
PC
5
Paulson & Co
New York
$13.2M – – –
NC
6
Nexthera Capital
New York
$13M +$409K +14,913 +3%
Wells Fargo
7
Wells Fargo
California
$9.13M -$202K -7,364 -2%
Morgan Stanley
8
Morgan Stanley
New York
$6.12M +$5.58M +203,694 +2,369%
Vanguard Group
9
Vanguard Group
Pennsylvania
$6.11M +$1.24M +45,372 +27%
PC
10
Pier Capital
Connecticut
$4.61M +$1.19M +43,408 +37%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$1.79M +$262K +9,566 +18%
Northern Trust
12
Northern Trust
Illinois
$1.57M +$52.3K +1,907 +4%
State Street
13
State Street
Massachusetts
$1.54M +$526K +19,180 +56%
Ameriprise
14
Ameriprise
Minnesota
$1.49M +$68.5K +2,500 +5%
CI
15
Conning Inc
Connecticut
$1.44M – – –
Goldman Sachs
16
Goldman Sachs
New York
$461K +$439K +16,009 New
Bank of New York Mellon
17
Bank of New York Mellon
New York
$439K +$34.1K +1,243 +9%
ProShare Advisors
18
ProShare Advisors
Maryland
$420K +$400K +14,582 New
EDRH
19
Edmond de Rothschild Holding
Switzerland
$346K +$329K +12,000 New
VF
20
Virtu Financial
New York
$339K +$323K +11,783 New
Deutsche Bank
21
Deutsche Bank
Germany
$337K +$187K +6,836 +139%
VEA
22
Virtus ETF Advisers
New York
$318K +$303K +11,044 New
VFA
23
Virtus Fund Advisers
Connecticut
$318K +$303K +11,044 New
Charles Schwab
24
Charles Schwab
California
$286K – – –
TA
25
Teachers Advisors
New York
$264K – – –
1
2 3

DOVA Hedge Fund Activity: Q4 2017 in Review

48 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q4 2017, worth a combined $209M — up 30% from $160M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new DOVA positions and 8 closed out — a net gain of 9 holders — while 17 added to existing stakes and 6 trimmed.

The largest buyer was BlackRock, adding an estimated $9.55M. The largest seller was Fidelity Investments, cutting an estimated $3.26M.

  • 48 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q4 2017, up from 39 in Q3 2017.
  • Funds reported $209M of Dova Pharmaceuticals, Inc. Common Stock stock for Q4 2017, up 30% quarter-over-quarter.
  • 17 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q4 2017 and 8 closed out, a net change of +9 holders.
  • The largest Dova Pharmaceuticals, Inc. Common Stock buyer in Q4 2017 was BlackRock, an estimated $9.55M added.
  • The largest Dova Pharmaceuticals, Inc. Common Stock seller in Q4 2017 was Fidelity Investments, an estimated $3.26M sold.

Based on aggregated 13F filings for Q4 2017.